149 related articles for article (PubMed ID: 34867586)
1. Totally Implantable Venous Access Devices: A Randomized Controlled Trial on the Effect of Psychological Support on Quality of Life and Body Image (BI-PORT).
Pinto E; Granziera E; Cagol M; Cappellato S; Alfieri R; Mari V; Meroni M; Zagonel V; Conte P; Pilati P; Castoro C; Cavallin F; Scarpa M
Front Psychol; 2021; 12():703497. PubMed ID: 34867586
[No Abstract] [Full Text] [Related]
2. Evaluation of the perceptions and cosmetic satisfaction of breast cancer patients undergoing totally implantable vascular access device (TIVAD) placement.
Liberale G; El Houkayem M; Viste C; Bouazza F; Moreau M; El Nakadi I; Veys I
Support Care Cancer; 2016 Dec; 24(12):5035-5040. PubMed ID: 27495928
[TBL] [Abstract][Full Text] [Related]
3. Quality-of-life assessment: arm TIVAD versus chest TIVAD.
Burbridge B; Goyal K
J Vasc Access; 2016 Nov; 17(6):527-534. PubMed ID: 27768211
[TBL] [Abstract][Full Text] [Related]
4. Morbidity of chemotherapy administration and satisfaction in breast cancer patients: a comparative study of totally implantable venous access device (TIVAD) versus peripheral venous access usage.
Singh KR; Agarwal G; Nanda G; Chand G; Mishra A; Agarwal A; Verma AK; Mishra SK; Goyal P
World J Surg; 2014 May; 38(5):1084-92. PubMed ID: 24305930
[TBL] [Abstract][Full Text] [Related]
5. Home-based multidimensional survivorship programmes for breast cancer survivors.
Cheng KKF; Lim YTE; Koh ZM; Tam WWS
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011152. PubMed ID: 28836379
[TBL] [Abstract][Full Text] [Related]
6. Maintaining patency in totally implantable venous access devices (TIVAD): a time-to-event analysis of different lock irrigation intervals.
Palese A; Baldassar D; Rupil A; Bonanni G; Capellari Maria T; Contessi D; De Crignis L; Vidoni A; Piller Roner S; Zanini A
Eur J Oncol Nurs; 2014 Feb; 18(1):66-71. PubMed ID: 24100090
[TBL] [Abstract][Full Text] [Related]
7. No impact of central venous insertion site on oncology patients' quality of life and psychological distress. A randomized three-arm trial.
Biffi R; Orsi F; Pozzi S; Maldifassi A; Radice D; Rotmensz N; Zampino MG; Fazio N; Peruzzotti G; Didier F
Support Care Cancer; 2011 Oct; 19(10):1573-80. PubMed ID: 20803038
[TBL] [Abstract][Full Text] [Related]
8. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.
Biffi R; de Braud F; Orsi F; Pozzi S; Mauri S; Goldhirsch A; Nolè F; Andreoni B
Ann Oncol; 1998 Jul; 9(7):767-73. PubMed ID: 9739444
[TBL] [Abstract][Full Text] [Related]
9. Radio-opacity and incidental identified mechanical complications of totally implantable venous access devices placed in the chest.
Surov A; Rusner C; Weigand K; John E; Spielmann RP; Behrmann C
Acta Radiol; 2012 Nov; 53(9):1035-9. PubMed ID: 23028172
[TBL] [Abstract][Full Text] [Related]
10. Randomized Clinical Trial Evaluating Complications and Complication-Related Removal of Arm-Situated Power-Injectable and Non-Power-Injectable Totally Implanted Venous Access Devices among Cancer Patients.
Burbridge B; Plewes C; Stoneham G; Szkup P; Otani R; Babyn P; Bryce R
J Vasc Interv Radiol; 2018 May; 29(5):648-656.e3. PubMed ID: 29499999
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Quality of Life of Patients with Breast or Colon Cancer with an Arm Vein Port (TIVAD) Versus a Peripherally Inserted Central Catheter (PICC).
Burbridge B; Lim H; Dwernychuk L; Le H; Asif T; Sami A; Ahmed S
Curr Oncol; 2021 Apr; 28(2):1495-1506. PubMed ID: 33918869
[TBL] [Abstract][Full Text] [Related]
12. Internal jugular vein versus subclavian vein as the percutaneous insertion site for totally implantable venous access devices: a meta-analysis of comparative studies.
Wu S; Huang J; Jiang Z; Huang Z; Ouyang H; Deng L; Lin W; Guo J; Zeng W
BMC Cancer; 2016 Sep; 16(1):747. PubMed ID: 27658952
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of Percutaneous Puncture in Insertion of Totally Implantable Venous Access Devices in Pediatric Patients.
Choi JS; Park KM; Jung S; Hong KC; Jeon YS; Cho SG; Choe YM
Vasc Specialist Int; 2017 Sep; 33(3):108-111. PubMed ID: 28955700
[TBL] [Abstract][Full Text] [Related]
14. Totally implantable venous access devices: evaluation of complications and a prospective comparative study of two different port systems.
Hartkamp A; van Boxtel AJ; Zonnenberg BA; Witteveen PO
Neth J Med; 2000 Dec; 57(6):215-23. PubMed ID: 11099790
[TBL] [Abstract][Full Text] [Related]
15. Seat belt associated central line fracture--a previously unreported complication in cystic fibrosis.
Ghayyda SN; Roland D; Cade A
J Cyst Fibros; 2008 Sep; 7(5):448-9. PubMed ID: 18455967
[TBL] [Abstract][Full Text] [Related]
16. Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies: A randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life.
Bow EJ; Kilpatrick MG; Clinch JJ
J Clin Oncol; 1999 Apr; 17(4):1267. PubMed ID: 10561188
[TBL] [Abstract][Full Text] [Related]
17. Is there any effect of first-day usage of a totally implantable venous access device on complications?
Karanlik H; Odabas H; Yildirim I; Ozgur I; Kilic B; Sen F; Kurul S; Aydiner A
Int J Clin Oncol; 2015 Dec; 20(6):1057-62. PubMed ID: 25911604
[TBL] [Abstract][Full Text] [Related]
18. Does systemic antibiotic prophylaxis prior to the placement of totally implantable venous access devices reduce early infection? A retrospective study of 1,485 cases at a large academic institution.
Choksi A; Finnegan K; Etezadi V
Am J Infect Control; 2020 Jan; 48(1):95-99. PubMed ID: 31439370
[TBL] [Abstract][Full Text] [Related]
19. Clinical and dosimetric impact of totally implantable venous access devices in radiotherapy of supra diaphragmatic Hodgkin Lymphoma.
Laurans M; Kirov K; Costa E; Lefebvre D; Kirova YM
Cancer Radiother; 2021 Feb; 25(1):32-38. PubMed ID: 33402292
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
